# SunRISe-4 (NCT04919512)

> A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04919512
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Urinary Bladder Neoplasms
- Interventions: TAR-200; Cetrelimab
- Enrollment: 163
- Primary outcome: Pathologic Complete Response (pCR) Rate

## Commentary we found

- YouTube: 49
- X threads: 45
- Podcasts: 24

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=sunrise-4-nct04919512

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04919512", "email": "<work email>"}; the inbox owner confirms by the emailed link.